Patent · US Active

Uracyl spirooxetane nucleoside phosphoramidates

US9012428B2 · kind B2 · utility

27Cited by

1References

9Claims

0Family size

Assignees

Janssen Products, LP · US
MEDIVIR AB · SE

Inventors

Tim Hugo Maria Jonckers · Heist-op-den-Berg, BE
Pierre Jean-Marie Bernard Raboisson · Sligo, IE
Koen Vandyck · Beringen, BE
Steven Maurice Paula Van Hoof · Merelbeke, BE
Lili Hu · Mechelen, BE
Abdellah Tahri · Anderlecht, BE

Key dates

Filing date	Nov 10, 2011
Grant date	Apr 21, 2015
Priority date	—
Expiry date	Nov 12, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K9/2068
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to a stereochemically pure uracyl spirooxetane nucleoside phosphoramidate useful in the treatment of patients infected with the hepatitis C virus (HCV).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.